Aorta-CAD vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Aorta-CAD

by Imagen Technologies

ElucidVivo A.3

by Elucid

AI Verdict

Aorta-CAD is designed for the initial detection of aortic atherosclerosis and ectasia on chest X-rays, aiming to reduce misses in frontline diagnostics. In contrast, ElucidVivo A.3 provides advanced quantitative analysis of arterial plaque composition and stability from CT angiography, assisting in patient stratification and optimizing treatment decisions for established atherosclerosis. While both address cardiovascular imaging, their distinct modalities and clinical applications position them as complementary rather than direct competitors.

Choose Aorta-CAD if…

Choose Aorta-CAD if your primary objective is to enhance the detection of early signs of Aortic Atherosclerosis and Aortic Ectasia on routine chest X-rays. This cloud-based software is ideal for improving the accuracy of frontline diagnostic imaging and assisting physicians, including PCPs, in quickly identifying potential aortic conditions within existing X-ray reading workflows.

View Aorta-CAD →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require detailed, quantitative analysis of arterial plaque composition and stability from CT angiography for advanced patient stratification and treatment optimization. This tool is best suited for cardiologists, radiologists, and vascular surgeons seeking to visualize and measure specific plaque characteristics, such as Lipid-Rich Necrotic Core (LRNC) and calcifications, to inform critical cardiovascular care decisions.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Aorta-CAD	ElucidVivo A.3
Pricing	Contact for pricing	Unknown
Deployment	Cloud-based	Cloud and on-premise secure deployment.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Aorta-CAD

Tool A emphasizes seamless integration into existing X-ray reading workflows and provides annotations via an overlay that can be toggled on/off, suggesting a non-disruptive and easy-to-adopt user experience. Tool B offers advanced 3D visualization and detailed views, which while powerful, might imply a steeper learning curve or more intensive user interaction compared to Tool A's simpler integration for frontline use.

Clinical Value

ElucidVivo A.3

While Tool A demonstrates significant value in reducing misses for aortic conditions on chest X-rays, Tool B provides a deeper, quantitative analysis of arterial plaque composition and stability from CT angiography, including objective quantification of LRNC, matrix, and calcifications, and derivation of FFRct. This detailed analysis, validated against ground-truth histology, offers more profound insights for patient stratification and optimizing treatment decisions in atherosclerosis, moving beyond mere detection to precision diagnostics.

Pricing & Value

Tie

Both tools state 'contact for pricing' and do not provide any public details regarding their cost structure. Without specific pricing information or publicly available case studies on ROI, it is impossible to compare their value proposition directly.

Enterprise Readiness

Aorta-CAD

Tool A explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA), which are critical for enterprise adoption in healthcare. Its cloud-based deployment also suggests scalability and ease of management. While Tool B is FDA-cleared and its privacy policy mentions HIPAA compliance, the BAA is not explicitly stated in the provided facts, and its deployment is described as 'likely on-premise or cloud-based,' making Tool A's readiness more clearly defined.

Innovation

ElucidVivo A.3

Both tools leverage AI, but Tool B demonstrates a higher degree of innovation by providing AI-powered quantitative analysis of arterial plaque composition and stability, including the objective quantification of specific plaque components and the derivation of fractional flow reserve (FFRct). This advanced analytical capability, coupled with validation against ground-truth histology, represents a more novel and sophisticated approach to understanding and managing atherosclerosis compared to Tool A's detection capabilities on X-rays.

Support & Docs

Tie

Neither the provided structured facts nor readily available public information from web searches offer sufficient detail about the specific support services, documentation, or training programs offered by either Imagen Technologies for Aorta-CAD or Elucid Bioimaging for ElucidVivo A.3 to make a meaningful distinction. Both companies generally mention support and training on their websites.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Aorta-CAD	ElucidVivo A.3
Name	Aorta-CAD	ElucidVivo A.3
Company	Imagen Technologies	Elucid Bioimaging
Primary Imaging Modality	Chest X-rays	CT angiography
Conditions Detected/Analyzed	Aortic Atherosclerosis, Aortic Ectasia	Arterial plaque composition and stability (atherosclerosis patient stratification)
Key Analysis Type	Detection and highlighting of radiographic findings	Quantitative analysis of arterial plaque composition (LRNC, matrix, calcifications), 3D visualization, FFRct derivation
Specialties	Cardiology, Internal Medicine, Radiology	Cardiology, Radiology, Vascular Surgery

Videos

Demos, reviews, and walkthroughs featuring Aorta-CAD and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do Aorta-CAD and ElucidVivo A.3 integrate into different clinical workflows, and what distinct clinical problems do they address?

Aorta-CAD seamlessly integrates into existing X-ray reading workflows, assisting physicians in detecting signs of Aortic Atherosclerosis and Aortic Ectasia on chest X-rays, primarily for frontline diagnostic imaging. ElucidVivo A.3, on the other hand, provides quantitative analysis of arterial plaque composition and stability from CT angiography, aiding in atherosclerosis patient stratification and optimizing treatment decisions with detailed plaque characteristics.

What is the demonstrated accuracy and specific clinical value proposition of each tool in identifying and characterizing cardiovascular conditions?

Aorta-CAD has demonstrated a 62% relative reduction in misses for aortic calcification and a 35% relative reduction in misses for dilated aorta in clinical studies, improving frontline diagnostic accuracy. ElucidVivo A.3 offers AI-powered quantitative analysis of arterial plaque composition (e.g., Lipid-Rich Necrotic Core, calcifications) from CT images, validated against histology, and derives fractional flow reserve (FFRct), providing detailed insights for patient stratification and treatment planning.

For which specific medical specialties and clinical use cases is each tool most appropriate?

Aorta-CAD is well-suited for Cardiology, Internal Medicine, and Radiology, assisting both radiologists and PCPs in interpreting chest X-rays for early signs of aortic conditions. ElucidVivo A.3 is designed for Cardiology, Radiology, and Vascular Surgery, providing advanced plaque analysis for stratifying atherosclerosis patients and guiding complex treatment decisions.

What is the expected learning curve for physicians to effectively utilize each tool, and how do they interact with the AI findings?

Aorta-CAD is designed for seamless integration into existing X-ray reading workflows, creating toggleable overlay annotations on X-rays, suggesting a relatively low learning curve for physicians to review AI findings. ElucidVivo A.3, with its detailed quantitative analysis, 3D visualizations, and FFRct derivation, likely requires a more specialized understanding and interaction for comprehensive interpretation and treatment planning, potentially implying a steeper learning curve.

Do these tools offer features for auditing AI-generated findings or provide transparency into their analytical process?

Aorta-CAD assists physicians by highlighting radiographic findings via an overlay that can be toggled on or off, indicating that the physician maintains control and can audit the AI's suggestions. ElucidVivo A.3 provides objective quantification of plaque components and 3D visualizations, offering a detailed, measurable output that supports physician review and understanding of the AI's analysis, with its plaque characterization validated against histology.

What are the key considerations for deploying these tools across multiple clinical sites or hospital systems?

For Aorta-CAD, its cloud-based nature suggests easier scalability and potentially less on-site IT burden for multi-site rollouts, requiring consistent internet access and integration with existing X-ray workflows across sites. ElucidVivo A.3, described as a software application that integrates with PACS/EMR, would require careful planning for integration with diverse PACS/EMR systems and potentially local IT infrastructure considerations across multiple sites.